Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Northern Trust Corp

Northern Trust Corp boosted its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 11.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 348,983 shares of the company's stock after purchasing an additional 34,693 shares during the quarter. Northern Trust Corp owned approximately 0.68% of Spyre Therapeutics worth $8,124,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. FMR LLC increased its holdings in Spyre Therapeutics by 15.4% during the 4th quarter. FMR LLC now owns 8,801,266 shares of the company's stock worth $204,893,000 after purchasing an additional 1,177,385 shares during the last quarter. Vanguard Group Inc. increased its holdings in Spyre Therapeutics by 13.1% during the 4th quarter. Vanguard Group Inc. now owns 2,846,473 shares of the company's stock worth $66,266,000 after purchasing an additional 330,553 shares during the last quarter. Wellington Management Group LLP increased its holdings in Spyre Therapeutics by 6.5% during the 4th quarter. Wellington Management Group LLP now owns 1,604,508 shares of the company's stock worth $37,353,000 after purchasing an additional 97,308 shares during the last quarter. Pictet Asset Management Holding SA increased its holdings in Spyre Therapeutics by 32.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,092,124 shares of the company's stock worth $25,425,000 after purchasing an additional 266,418 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Spyre Therapeutics by 8.4% during the 4th quarter. Geode Capital Management LLC now owns 966,129 shares of the company's stock worth $22,498,000 after purchasing an additional 75,081 shares during the last quarter. 80.39% of the stock is currently owned by hedge funds and other institutional investors.

Spyre Therapeutics Price Performance

Shares of NASDAQ SYRE traded down $0.06 during mid-day trading on Friday, hitting $15.01. The company had a trading volume of 210,288 shares, compared to its average volume of 613,576. The stock has a market cap of $904.74 million, a price-to-earnings ratio of -2.01 and a beta of 2.78. Spyre Therapeutics, Inc. has a 12 month low of $10.91 and a 12 month high of $40.26. The firm's 50 day simple moving average is $14.59 and its two-hundred day simple moving average is $20.68.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.02. Equities analysts forecast that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on SYRE shares. Leerink Partners started coverage on Spyre Therapeutics in a report on Tuesday, April 8th. They set an "outperform" rating and a $45.00 target price on the stock. Wedbush reaffirmed an "outperform" rating and set a $65.00 target price on shares of Spyre Therapeutics in a report on Monday, May 5th. Leerink Partnrs raised Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, April 8th. The Goldman Sachs Group raised Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, February 18th. Finally, Wolfe Research began coverage on Spyre Therapeutics in a report on Tuesday, March 18th. They set an "outperform" rating and a $27.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $53.40.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).